SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies unveils Taxedol in India

09 Jul 2012 Evaluate

Venus Remedies, a leading research based global pharmaceutical company has introduced for the first time a nanotechnology based ‘Ready-to-Use’ Single Vial Docetaxel in the domestic market under the brand name ‘Taxedol’. Taxedol is ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml.

Taxedol (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff. Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.

Taxedol, a ‘Ready-to-Use’ single vial will not only weed out the competition from other players in the market but the company is hopeful of capturing significant share in Rs 1,500 crore Indian Cancer Drug Industry, which is speculated to show a steady growth over the coming few years.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×